Eledon Pharmaceuticals (ELDN) Preferred Stock Liabilities (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 7 years of Preferred Stock Liabilities data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.2 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities was little changed at $2.2 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $53.5 million in Q4 2023 to a low of $2.2 million in Q2 2024.
• A 5-year average of $11.6 million and a median of $2.2 million in 2024 frame the typical range for Preferred Stock Liabilities.
• Annual changes were most pronounced in 2023 — Preferred Stock Liabilities soared 1674.71% — and 2024, when it slumped 95.98%.
• Tracing ELDN's Preferred Stock Liabilities over 5 years: stood at $3.0 million in 2022, then soared by 1674.71% to $53.5 million in 2023, then tumbled by 95.98% to $2.2 million in 2024, then changed by 0.0% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• The last three Preferred Stock Liabilities figures came in at $2.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.